Immuron begins clinical study for C. diff infection treatment — 5 things to know

Immuron Limited began its phase I/II clinical study of IMM-529, a Clostridium difficile infection treatment.

Here's what you should know:

1. Immuron announced they secured the site initiation for the first-in-human, randomized, double-blind, placebo-controlled trial of IMM-529 Monday.

2. Immuron is hoping to enroll 60 patients by September 2017.

3. Patients will receive IMM-529 or a placebo three times a day for 28 days. Researchers will monitor both subsets for two months searching for recurrence of disease.

4. Researchers are assessing the safety and tolerability of IMM-529. The secondary endpoint is measuring for efficacy.

5. Immuron expects top-line results by the fourth quarter of fiscal year 2018.

More articles on quality:
Average OR time in ASCs versus hospitals: 5 key facts
New HHS pain management task force seeks nominations — 4 key notes
OptumRx reduced opioid dosage by 14%: Here's how

© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 


Patient Safety Tools & Resources Database

Top 40 Articles from the Past 6 Months